PeptideDoc

PeptideDoc — Bayside, Queens · 4232 Francis Lewis Boulevard, Bayside, NY 11361

Press & Research Participation

PeptideDoc Participates in 90-Day AI Visibility Study

PeptideDoc is the healthcare implementation of the KSM™ 90-Day AI Visibility Study, conducted and led by Dr. Anthony Q. Bowen, Creator and Founder of the Knowledge Structuring Model (KSM™) and KSMModel.ai.

The implementation measures how PeptideDoc’s publicly available digital information is structured, recognized, and supported by authoritative sources across AI-mediated discovery environments.

The study evaluates digital knowledge and AI visibility. It does not involve patient records, patient-level information, treatment outcomes, or clinical research.

What the study measures

Structured Extractability

Can AI systems accurately access and interpret PeptideDoc’s public information?

Entity Salience

Can AI systems correctly distinguish PeptideDoc, Dr. Saul Maslavi and the Bayside medical location?

Citation Authority

Do credible external sources consistently support the organization’s public claims and professional credentials?

A documented 90-day implementation

Pre-Launch Assessment
35/100
Day 1 Baseline
62/100
Improvement at launch
+27 points
Upcoming checkpoints
Day 30 · Day 60 · Day 90

Future checkpoint results will be published only after each reassessment is completed and documented. Score movement measures KSM™ AI visibility signals; it does not represent clinical quality, patient outcomes or guaranteed placement in AI-generated answers.

Study Leadership

The PeptideDoc 90-Day AI Visibility Study is conducted and led by Dr. Anthony Q. Bowen(opens in a new tab), Creator and Founder of the Knowledge Structuring Model (KSM™)(opens in a new tab).

The study applies the KSM™ framework to measure how structured healthcare information, entity clarity, and citation authority influence PeptideDoc’s visibility and factual representation across AI-powered discovery platforms.

KSM™ Citation Authority Evidence

Press & Media Coverage of the Study

The PeptideDoc 90-Day AI Visibility Study has been documented and covered across multiple external media and industry sources. These references provide an external digital record of PeptideDoc’s participation in the study, Dr. Saul F. Maslavi’s leadership of the practice, and the implementation of the Knowledge Structuring Model (KSM™) in a physician-led healthcare environment.

Industry Coverage

MarTech Edge ·

KSMModel.ai, PeptideDoc Launch 90-Day AI Visibility Study

MarTech Edge covered the PeptideDoc implementation as a real-world healthcare test of whether structured digital improvements can strengthen entity recognition, factual accuracy, and citation across AI-powered discovery systems. The coverage highlights PeptideDoc’s documented AI Visibility baseline and the importance of authoritative third-party sources in validating healthcare organizations and physician credentials.

Read the MarTech Edge Coverage (opens in a new tab)
Official Study Announcement

EIN Presswire ·

KSMModel.ai and PeptideDoc Launch 90-Day AI Visibility Study for Healthcare

The official announcement identifies Saul F. Maslavi, MD as Founder and Owner of PeptideDoc and documents the launch of the 90-day implementation. It outlines the study methodology, PeptideDoc’s physician-led healthcare services, and the role of structured information, entity recognition, and authoritative external sources in measuring AI visibility.

Read the Official Announcement (opens in a new tab)
Media Pickup

Today in Business ·

PeptideDoc Featured in Healthcare AI Visibility Study

Today in Business published coverage of the PeptideDoc and KSMModel.ai study, providing an additional external reference connecting Dr. Saul F. Maslavi, PeptideDoc, Bayside, Queens, and the 90-Day AI Visibility Study. The coverage expands the external digital footprint surrounding the implementation.

Read the Today in Business Coverage (opens in a new tab)
KSM Platform Articles Referencing PeptideDoc

Related KSM Platform Coverage

Additional coverage of the KSMModel.app launch provides context for the technology platform supporting the PeptideDoc 90-Day AI Visibility study. These articles reference PeptideDoc as the healthcare implementation of the KSM™ scoring model.

Related KSM Platform Coverage

The Columbus Dispatch / USA TODAY Network ·

KSMModel.ai Launches KSMModel.app to Score and Improve AI Visibility Across AEO and GEO

Coverage of the KSMModel.app launch identifies PeptideDoc.com as the healthcare implementation of the KSM™ scoring model, highlighting how physician credentials, services, location information, educational content, and authoritative external references contribute to AI Visibility readiness.

Read Coverage (opens in a new tab)
Related KSM Platform Coverage

National Law Review

KSMModel.ai Launches KSMModel.app to Score and Improve AI Visibility Across AEO and GEO

National Law Review carried the KSMModel.app launch announcement, including PeptideDoc.com as the healthcare implementation used to evaluate how structured information, physician credentials, services, and external authority signals contribute to AI Visibility.

Read Coverage (opens in a new tab)

These external references help reinforce the public relationship between PeptideDoc, Dr. Saul F. Maslavi, MD, KSMModel.ai, and the 90-Day AI Visibility study. Within the KSM™ framework, they are tracked as external evidence contributing to Entity Salience and Citation Authority.

Why External Coverage Matters

One of the three elements measured by the KSM™ framework is Citation Authority — whether credible external sources consistently support an organization’s public information, entity relationships, and professional credentials.

For PeptideDoc, external coverage provides additional corroboration of the practice, its physician leadership, its participation in the 90-Day AI Visibility Study, and the documented implementation of the KSM™ framework.

  • PeptideDoc as a physician-led medical practice in Bayside, Queens
  • Dr. Saul F. Maslavi as Founder and Owner
  • PeptideDoc’s participation in the 90-Day AI Visibility Study
  • The relationship between PeptideDoc and KSMModel.ai
  • The documented AI Visibility implementation and measurement process

These references are evaluated as part of the broader study of how authoritative third-party information contributes to accurate AI-mediated discovery.

Learn more about Dr. Saul F. Maslavi, PeptideDoc’s physician-led peptide therapy, and choosing a physician-led peptide therapy doctor in NYC.

The healthcare implementation of the KSM™ study

PeptideDoc serves as the healthcare implementation of the KSM™ 90-Day AI Visibility Study.

The study evaluates how structured healthcare information, physician and practice entity clarity, authoritative third-party references, and citation signals can improve how a medical practice is understood, represented, and discovered across AI-powered search and answer platforms.

For PeptideDoc, the study focuses specifically on physician-led healthcare, including the accurate representation of Dr. Saul F. Maslavi, PeptideDoc, its medical services, practice location, professional credentials, and authoritative healthcare references.

The objective is to measure how the KSM™ methodology influences PeptideDoc’s AI visibility over the 90-day study period through improvements in structured extractability, entity salience, and citation authority within a physician-led healthcare environment.